170 related articles for article (PubMed ID: 38252229)
1. Performance of
Guo H; Wu S; Xiang X; Wang S; Fang Z; Ye Q; Zou Y; Wang Y; Peng D; Ma X
Ann Nucl Med; 2024 Apr; 38(4):288-295. PubMed ID: 38252229
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive detection and differentiation of cardiac amyloidosis using
Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
[TBL] [Abstract][Full Text] [Related]
3. A Gluteus Medius Muscle Biopsy to Confirm Amyloid Transthyretin Deposition in Wild-type Transthyretin Cardiac Amyloidosis: A Report of Two Cases.
Takahashi K; Iwamura T; Hiratsuka Y; Sasaki D; Yamamura N; Ueda M; Morioka H; Yoshino M; Enomoto D; Uemura S; Okura T; Sakaue T; Ikeda S
Intern Med; 2024 Jun; 63(11):1575-1584. PubMed ID: 37899242
[TBL] [Abstract][Full Text] [Related]
4. Bilateral Multiple Fractures Obstruct Quantitation of 99m Tc-Pyrophosphate Imaging for Cardiac Amyloidosis.
Zhou Q; Zuo J; Xiao L; Jiang L; Zhao Z
Clin Nucl Med; 2024 Jul; 49(7):e362-e363. PubMed ID: 38651782
[TBL] [Abstract][Full Text] [Related]
5. Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.
Papantoniou V; Valsamaki P; Kastritis S; Tsiouris S; Delichas Z; Papantoniou Y; Tsiouma M; Athanasoulis T; Fotopoulos A; Dimopoulos MA
Hell J Nucl Med; 2015; 18 Suppl 1():42-50. PubMed ID: 26665211
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 1-h with 3-h planar
Saitou T; Aikawa T; Manabe O; Nagase A; Kudo T; Oyama-Manabe N
Ann Nucl Med; 2023 Feb; 37(2):99-107. PubMed ID: 36352186
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
Castano A; Haq M; Narotsky DL; Goldsmith J; Weinberg RL; Morgenstern R; Pozniakoff T; Ruberg FL; Miller EJ; Berk JL; Dispenzieri A; Grogan M; Johnson G; Bokhari S; Maurer MS
JAMA Cardiol; 2016 Nov; 1(8):880-889. PubMed ID: 27557400
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.
Poterucha TJ; Elias P; Bokhari S; Einstein AJ; DeLuca A; Kinkhabwala M; Johnson LL; Flaherty KR; Saith SE; Griffin JM; Perotte A; Maurer MS
JACC Cardiovasc Imaging; 2021 Jun; 14(6):1221-1231. PubMed ID: 33221204
[TBL] [Abstract][Full Text] [Related]
9. Serial scanning with technetium pyrophosphate (
Castaño A; DeLuca A; Weinberg R; Pozniakoff T; Blaner WS; Pirmohamed A; Bettencourt B; Gollob J; Karsten V; Vest JA; Chiuzan C; Maurer MS; Bokhari S
J Nucl Cardiol; 2016 Dec; 23(6):1355-1363. PubMed ID: 26453570
[TBL] [Abstract][Full Text] [Related]
10. Inverse correlation between age of onset and myocardial amyloid deposition quantified by
Kanaya H; Shiraishi S; Ogasawara K; Iwashita K; Sakamoto F; Takashio S; Mikami Y; Tsujita K; Hirai T
Ann Nucl Med; 2024 Jun; ():. PubMed ID: 38874878
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of heart-to-mediastinum ratio in
Ikoma T; Ohtani H; Ohno K; Iguchi K; Suwa K; Sawada M; Tanahashi Y; Sakamoto A; Saotome M; Ichikawa S; Goshima S; Maekawa Y
J Nucl Cardiol; 2023 Aug; 30(4):1374-1381. PubMed ID: 36547805
[TBL] [Abstract][Full Text] [Related]
12. A case report of an uncommon presentation of
Ochi Y; Kubo T; Nakashima Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
J Cardiol Cases; 2020 Feb; 21(2):50-53. PubMed ID: 32042354
[No Abstract] [Full Text] [Related]
13. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc
Pandey S; Teruya S; Rodriguez C; Deluca A; Kinkhabwala M; Johnson LL; Fine D; Sabogal N; Winburn M; Castillo M; Bhatia K; Malkovskaya R; Raiszadeh F; Kurian D; Miller EJ; Einstein AJ; Maurer MS; Ruberg FL
J Nucl Cardiol; 2023 Aug; 30(4):1414-1419. PubMed ID: 36823486
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Kumamoto criteria for prediction of
Ochi Y; Kubo T; Baba Y; Ueda M; Miyagawa K; Noguchi T; Hirota T; Yamasaki N; Kitaoka H
J Cardiol; 2021 Feb; 77(2):124-130. PubMed ID: 33132078
[TBL] [Abstract][Full Text] [Related]
15. Optimizing cardiac amyloidosis assessment: utility of 1-h and 3-h
Imakhanova A; Ideguchi R; Kawano H; Maemura K; Kudo T
Eur J Med Res; 2024 Jan; 29(1):32. PubMed ID: 38184638
[TBL] [Abstract][Full Text] [Related]
16. Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis.
Lee TH; Wang YF; Hu LH; Peng NJ; Chang CY; Huang WS
Jpn J Radiol; 2023 Aug; 41(8):882-888. PubMed ID: 36920732
[TBL] [Abstract][Full Text] [Related]
17. Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis.
Waheed A; Dorbala S
Cardiol Clin; 2023 May; 41(2):217-231. PubMed ID: 37003679
[TBL] [Abstract][Full Text] [Related]
18. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population.
Bourque JM; Schepart A; Bhambri R; Castaño A; O'Brien A; Chen Y; Prasad S; Roy A; Grodin JL
Am J Cardiol; 2022 Mar; 167():98-103. PubMed ID: 35022130
[TBL] [Abstract][Full Text] [Related]
19. Standardization of
Bokhari S; Morgenstern R; Weinberg R; Kinkhabwala M; Panagiotou D; Castano A; DeLuca A; Kontak A; Jin Z; Maurer MS
J Nucl Cardiol; 2018 Feb; 25(1):181-190. PubMed ID: 27580616
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
